Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
The main adverse effects to be expected from the use of rFVIIa is the occurrence of thromboembolic complications. This study reviews the occurrence of adverse effects reported to the FDA […]
Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study.
Cardiac surgery is often associated with excessive blood component transfusion especially with complex and repeat procedures, and is therefore an obvious target for blood saving measures. There have been several […]
Recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.
This is a small series of case reports on using rFVIIa in treating severe perioperative hemorrhage in 8 patients undergoing major vascular surgeries, contributing to effective hemostasis in 7 of […]
Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.
The etiology of severe hemorrhage associated with trauma includes coagulopathy, hypothermia, acidosis, as well as platelet dysfunction, in addition to the direct effect of trauma itself. This important large international […]
Off-label use of recombinant factor VIIA concentrates after cardiac surgery.
This article reviews the mechanism of action of rFVIIa and outlines its off-label use in management of perioperative bleeding and intracranial hemorrhage. Authors review the paper of Raivio et al […]
Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.
This is one center experience on the use of rFVIIa to treat severe postoperative bleeding following cardiac surgery after failure of conventional therapy with blood components and hemostatic agents. Bleeding […]
Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial.
This randomized study did not show significant difference between perioperative blood loss or blood transfusion requirement by prophylactic use of rFVIIa in patients with normal hemostasis undergoing pelvic surgery. No […]
Is recombinant FVIIa the magic bullet in the treatment of major bleeding? [Editorial]
This editorial reviews the use of rFVIIa in management of surgical and post-partum hemorrhage and highlights that in spite of anecdotal evidence from published case reports and small series of […]
First military use of activated Factor VII in an APC-III pelvic fracture.
This case report illustrates the efficacy and benefit of using rFVIIa in controlling severe bleeding associated with trauma which resulted in severe pelvic and sacral fracture. The authors advocate further […]
Recombinant activated factor VII for acute intracerebral hemorrhage.
This is an extremely important, long-awaited study on the effect of rFVIIa in management of intracerebral haemorrhage. It is a double-blind, placebo-controlled study which enrolled 399 patients into control placebo […]
Stopping the bleeding in intracerebral hemorrhage. [Editorial]
This editorial reviews the work of Mayer et al. on the use of rFVIIa in patients who suffer intracerebral hemorrhage and gives a new hope of therapy which can prevent […]
The use of recombinant factor VIIa in a patient with essential thrombocythaemia with uncontrolled surgical bleeding.
Recombinant factor VIIa has been found to be effective in controlling bleeding associated with inherited and acquired platelet dysfunction, such as thromboasthenia and renal failure. In this case report, rFVIIa […]
Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage.
This is an interesting case report on the efficacy of rFVIIa in controlling bleeding in a complex situation of trauma, intracranial hemorrhage, and autoimmune thrombocytopenia. – Maadh Aldouri
Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial.
Liver surgery is known to be associated with significant blood loss and high requirement of blood products support, and rFVIIa has been shown in a few case reports to reduce […]
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
Thromboembolic (TE) events are recognized but rare complications associated with the use of factor VIII inhibitor bypass activity (FEIBA) and rFVIIa. This study looks at the reported TE events of […]